Mumbai, Sept. 16 -- Cenobamate, being launched for the first time in India, represents a significant advancement in the management of epilepsy. NeuCeno is a once daily oral therapy and is available in various strengths.

Epilepsy is a significant healthcare burden in India, with an estimated 9.4 million people living with the condition.

Despite the availability of multiple anti-seizure medications, a significant proportion of patients continue to experience uncontrolled seizures, substantially affecting their independence, daily functioning and overall quality of life.

NeuCeno (cenobamate) acts through a unique dual mechanism of action, selectively inhibiting the persistent sodium current that drives repetitive neuronal firing, while en...